Role of nitric oxide in rotenone-induced nigro-striatal injury

Journal of Neurochemistry

Volumn 86, Issue 6, 2003, Pages 1338-1345

  He, Yi ^a   Imam, Syed Z ^b   Dong, Zaojun ^c   Jankovic, Joseph ^a   Ali, Syed F ^b   Appel, Stanley H ^a   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Dopamipe; Nigro striatum; Nitric oxide; Parkinson's disease; Rotenone

Indexed keywords

3 NITROTYROSINE; 7 NITROINDAZOLE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PESTICIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; NERVE CELL; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPTICAL DENSITY; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; BRAIN CHEMISTRY; CELL COUNT; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; INDAZOLES; INSECTICIDES; NADPH DEHYDROGENASE; NERVE DEGENERATION; NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE I; PEROXYNITROUS ACID; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TIME; TYROSINE 3-MONOOXYGENASE; UNCOUPLING AGENTS;

ANIMALIA;

EID: 0141767129     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01938.x     Document Type: Article

References (40)

1. Ara J., Przedborski S., Ali B. N., Jackson-Lewis V., Trifiletti R. R., Horwitz J. and Ischiropoulos H. (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc. Natl Acad. Sci. USA 95, 7659-7663.
2. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. and Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
3. Cadet J. L. and Brannock C. (1998) Free radicals and pathobiology of brain dopamine systems. Neurochem. Int. 32, 117-131.
4. Dehmer T., Lindenau J., Haid S., Dichgans J. and Schulz J. B. (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74, 2213-2216.
5. Desai V. G., Feuers R. J., Hart R. W. and Ali S. F. (1996) MPP(+) -induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. Brain Res. 715, 1-8.
6. Elbaz A., Grigoletto F., Baldereschi M., Breteler M. M., Manubens-Bertran J. M., Lopez-Pousa S., Dartigues J. F., Alperovitch A., Tzourio C. and Rocca W. A. (1999) Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. EUROPARKINSON Study Group. Neurology 52, 1876-1882.
7. Ferrante R. J., Schulz J. B., Kowall N. W. and Beal M. F. (1997) Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 753, 157-162.
8. Freyaldenhoven T. E., Ali S. F. and Schmued L. (1997) Systemic administration of MPTP induces thalamic neuronal degeneration in mice. Brain Res. 759, 9-17.
9. Gao H. M., Hong J. S., Zhang W. and Liu B. (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22, 782-790.
10. Gonzalez-Hernandez T., Abdala P. and Rodriguez M. (1997) NOS expression in nigral cells after excitotoxic and nono-excitoxic lesion of the pedunculopontine tegmental nucleus. Eur. J. Neurosci. 9, 2658-2667.
11. Gorell J. M., Johnson C. C., Rybicki B. A., Peterson E. L. and Richardson R. J. (1998) The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50, 1346-1350.
12. Gutman M., Singer T. P. and Casida J. E. (1970) Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. XVII. Reaction sites of piericidin A and rotenone. J. Biol. Chem. 245, 1992-1997.
13. Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R. T. and Beal M. F. (1996) Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2, 1017-1021.
14. Heikkila R. E., Nicklas W. J., Vyas I. and Duvoisin R. C. (1985) Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci. Lett. 62, 389-394.
15. Hensley K., Pye Q. N., Maidt M. L., Stewart C. A., Robinson K. A. and Floyd R. A. (1998) Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex 1 indicates a substrate reduction site upstream from the rotenone binding site. J. Neurochem. 71, 2549-2557.
16. Hoglinger G., Feger J., Prigent A., Michel P., Parain K., Champy P., Ruberg M., Oertel W. and Hirsh E. (2003) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84, 491-502.
17. Hope B. T., Micheal G. J., Knigge K. M. and Vincent S. R. (1991) Neuronal NADPH-diaphorase is a nitric oxide synthase. Proc. Natl Acad. Sci. USA 88, 2811-2814.
18. Hsieh P. F., Chia L., Ni D., Cheng L., Ho Y., Tzeng S., Chang M. and Hong J. (2002) Behavior, neurochemistry and histology after intranigral lipopolysaccharide injection. Neuroreport 13, 277-280.
19. Imam S. Z. and Ali S. F. (2001) Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: correlation with peroxynitrite production and hyperthermia. J. Neurochem. 78, 1-10.
20. Imam S. Z., Newport G. D., Itzhak Y., Cadet J. L., Islam F., Slikker W. and Ali S. F. Jr. (2001) Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J. Neurochem. 76, 745-749.
21. Johansson R., Pandita R., Poljakovic M., Garcia-Pascual A., Vente J. and Persson K. (2002) Activity and expression of nitric oxide synthase in the hypertrophied rat bladder and the effect of nitric oxide on bladder smooth muscle growth. J. Urol. 168, 2689-2694.
22. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y. and Shimizu N. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
23. Klivenyi P., Andreassen O. A., Ferrante R. J., Lancelot E., Reif D. and Beal M. F. (2000) Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport 11, 1265-1268.
24. Koeberle P. D. and Ball A. K. (1999) Nitric oxide synthase inhibition delays axonal degeneration and promotes the survival of axotomized retinal ganglion cells. Exp. Neurol. 158, 366-381.
25. LaVoie M. J. and Hastings T. G. (1999) Peroxynitrite- and nitrite-induced oxidation of dopamine: implications for nitric oxide in dopaminergic cell loss. J. Neurochem. 73, 2546-2554.
26. Le W., Conneely O. M., He Y., Jankovic J. and Appel S. H. (1999a) Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J. Neurochem. 73, 2218-2221.
27. Le W., Conneely O. M., Zou L., He Y., Saucedo-Cardenas O., Jankovic J., Mosier D. R. and Appel S. H. (1999b) Selective agenesis of mesencephalic dopaminergic neurons in Nurr 1-deficient mice. Exp. Neurol. 59, 451-458.
28. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M. J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P. J., Wilkinson K. D. and Polymeropoulos M. H. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
29. Liberatore G. T., Jackson-Lewis V., Vukosavic S., Mandir A. S., Vila M., McAuliffe W. G., Dawson V. L., Dawson T. M. and Przedborski S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat. Med. 5, 1403-1409.
30. Marey-Semper I., Gelman M. and Levi-Strauss M. (1995) A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J. Neurosci. 15, 5912-5918.
31. Menegon A., Board P. G., Blackbum A. C., Mellick G. D. and Le D. G. (1998) Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352, 1344-1346.
32. Parker W. D., Boyson S. J. and Parks J. K. (1989) Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26, 719-723.
33. Piccini P., Burn D. J., Ceravolo R., Maraganore D. and Brooks D. J. (1999) The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann. Neurol. 45, 577-582.
34. Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E. S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johanson W. G., Lazzarini A. M., Duvoisin R. C., Di Iorio G., Golbe L. I. and Nussbaum R. L. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
35. Porter R. H. P., Greene J. G., Higgins D. S. and Greenamyre J. T. (1994) Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilatral dopamine depletion. J. Neurosci. 14, 7192-7199.
36. Schapira A. H., Gu M., Taanman J. W., Tabrizi S. J., Seaton T., Cleeter M. and Cooper J. M. (1998) Mitochondria in the etiology and pathogenesis of Parkinson's disease. Ann. Neurol. 44, S89-S98.
37. Seaton T. A., Cooper J. M. and Schapira A. H. V. (1997) Free radical scavengers protest dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777, 110-118.
38. Sherer T., Kim J., Betarbet R. and Greenamyre T. (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation. Exp. Neurol. 179, 9-16.
39. Thiffault C., Langston J. W. and Di Monte D. A. (2000) Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res. 885, 283-288.
40. Thiruchelvam M., Richfield E. K., Baggs R. B., Tank A. W. and Cory-Slechta D. A. (2000) The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20, 9207-9214.